Results 81 to 90 of about 1,936 (153)

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

open access: yesBMC Infectious Diseases, 2017
Background A challenge in the empiric treatment of complicated urinary tract infection (cUTI) is identifying the initial appropriate antibiotic therapy (IAAT), which is associated with reduced length of stay and mortality compared with initial ...
Teresa L Kauf   +7 more
doaj   +1 more source

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial

open access: yesInfectious Diseases and Therapy, 2020
Introduction Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU).
Thomas Lodise   +4 more
doaj   +1 more source

Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)

open access: yesInfection and Drug Resistance, 2022
Michael Pfaller,1,2 Dee Shortridge,1 Wei-Ting Chen,3 Helio Sader,1 Mariana Castanheira1 1JMI Laboratories, North Liberty, IA, USA; 2University of Iowa College of Medicine, Iowa City, IA, USA; 3Merck & Co., Inc, Kenilworth, NJ, USACorrespondence: Dee ...
Pfaller M   +4 more
doaj  

A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa

open access: yes
Objectives: To develop a scoring system to predict resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa strains isolated from respiratory specimens.
ÇAKIR, BANU   +7 more
core   +1 more source

In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa

open access: yes, 2017
Guidelines for the treatment of sepsis, febrile neutropenia, and hospital-acquired pneumonia caused by Pseudomonas aeruginosa include empirical regimens incorporating two antibiotics from different classes with activity against
Kellie J. Goodlet   +2 more
core   +1 more source

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways

open access: yesCase Reports in Infectious Diseases, 2018
Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed by ...
Erik Skoglund   +11 more
doaj   +1 more source

Ceftolozane/tazobactam: Novelantipseudomonal cephalosporin [PDF]

open access: yesPharmacy Today, 2015
Abstract Another much-needed antibiotic enters the marketplace with FDA'sapproval of ceftolozane/tazobactam (Zerbaxa—Cubist) for the treatmentof adult patients with complicated intra-abdominal infections(cIAI) in combination with metronidazole and for complicated urinarytract infections (cUTI), including pyelonephritis.
openaire   +1 more source

Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives

open access: yesBMC Microbiology
Objectives Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms ...
Léa Bientz   +13 more
doaj   +1 more source

Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024

open access: yesFrontiers in Cellular and Infection Microbiology
ObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Mark G. Wise   +5 more
doaj   +1 more source

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections [PDF]

open access: yes, 2015
Marion J Skalweit1,2 1Department of Medicine, 2Department of Biochemistry, Louis Stokes Cleveland Department of Veterans Affairs and Case Western Reserve University School of Medicine, Cleveland, OH, USA Abstract: Drug-resistant pathogens have gained a
Skalweit MJ
core  

Home - About - Disclaimer - Privacy